Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:ETON NASDAQ:KROS NASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.29-2.9%$5.64$1.85▼$7.18$892.94M1.182.42 million shs1.76 million shsETONEton Pharmaceuticals$29.13+0.8%$27.64$13.09▼$35.66$791.64M0.87400,195 shs236,567 shsKROSKeros Therapeutics$10.30-4.4%$11.33$9.79▼$22.55$213.16M0.94327,971 shs163,405 shsORICOric Pharmaceuticals$7.50-6.5%$9.38$7.23▼$14.93$830.21M1.041.58 million shs1.24 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+1.11%+1.49%-4.72%+5.62%+124.28%ETONEton Pharmaceuticals+4.67%-9.29%-4.87%+72.02%+70.50%KROSKeros Therapeutics+2.57%-5.44%-8.50%-4.69%-27.33%ORICOric Pharmaceuticals+2.30%-5.09%-16.20%-41.50%-11.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.29-2.9%$5.64$1.85▼$7.18$892.94M1.182.42 million shs1.76 million shsETONEton Pharmaceuticals$29.13+0.8%$27.64$13.09▼$35.66$791.64M0.87400,195 shs236,567 shsKROSKeros Therapeutics$10.30-4.4%$11.33$9.79▼$22.55$213.16M0.94327,971 shs163,405 shsORICOric Pharmaceuticals$7.50-6.5%$9.38$7.23▼$14.93$830.21M1.041.58 million shs1.24 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+1.11%+1.49%-4.72%+5.62%+124.28%ETONEton Pharmaceuticals+4.67%-9.29%-4.87%+72.02%+70.50%KROSKeros Therapeutics+2.57%-5.44%-8.50%-4.69%-27.33%ORICOric Pharmaceuticals+2.30%-5.09%-16.20%-41.50%-11.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00202.46% UpsideETONEton Pharmaceuticals 2.40Hold$41.0040.75% UpsideKROSKeros Therapeutics 2.25Hold$20.4098.06% UpsideORICOric Pharmaceuticals 2.73Moderate Buy$19.36158.18% UpsideCurrent Analyst Ratings BreakdownLatest KROS, ORIC, ETON, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ORICOric Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/15/2026KROSKeros Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/15/2026ORICOric Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$15.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/5/2026ORICOric Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.004/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AETONEton Pharmaceuticals$79.95M9.98$0.01 per share5,575.71$0.98 per share29.72KROSKeros Therapeutics$244.06M0.84$4.33 per share2.38$15.51 per share0.66ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.07N/A15.25N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)KROSKeros Therapeutics$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)Latest KROS, ORIC, ETON, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/14/2026Q1 2026KROSKeros Therapeutics-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35ETONEton Pharmaceuticals0.621.210.88KROSKeros TherapeuticsN/A22.6122.62ORICOric PharmaceuticalsN/A16.3316.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AETONEton Pharmaceuticals27.86%KROSKeros Therapeutics71.56%ORICOric Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipANNXAnnexon10.31%ETONEton Pharmaceuticals16.49%KROSKeros Therapeutics20.60%ORICOric Pharmaceuticals5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableETONEton Pharmaceuticals2027.39 million22.88 millionOptionableKROSKeros Therapeutics10019.79 million15.72 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableKROS, ORIC, ETON, and ANNX HeadlinesRecent News About These CompaniesORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5 at 4:30 PM | globenewswire.comORIC Pharmaceuticals Inc ORICMay 31, 2026 | morningstar.comMORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2026 | globenewswire.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Moderate Buy" by BrokeragesMay 27, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 21, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 19, 2026 | globenewswire.comCompanies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In GrowthMay 17, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 14, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 12, 2026 | globenewswire.comWall Street Zen Downgrades Oric Pharmaceuticals (NASDAQ:ORIC) to Strong SellMay 9, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICMay 7, 2026 | prnewswire.comQ2 EPS Estimate for Oric Pharmaceuticals Lowered by AnalystMay 7, 2026 | marketbeat.comORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational UpdatesMay 4, 2026 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICApril 28, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ...April 23, 2026 | bakersfield.comBORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the ...April 23, 2026 | caledonianrecord.comCINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORICApril 21, 2026 | globenewswire.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American ...April 17, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual MeetingApril 17, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Is Costco Preparing Another Special Dividend This Year?By Dan Schmidt | May 8, 2026The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsBy Jeffrey Neal Johnson | May 14, 2026Why Lam Research Still Looks Like a Buy After a 300% RallyBy Sam Quirke | May 7, 2026From Runway to Riches: Victoria's Secret's New LookBy Jeffrey Neal Johnson | June 4, 2026KROS, ORIC, ETON, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$5.29 -0.16 (-2.94%) Closing price 04:00 PM EasternExtended Trading$5.26 -0.03 (-0.57%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Eton Pharmaceuticals NASDAQ:ETON$29.13 +0.23 (+0.80%) Closing price 04:00 PM EasternExtended Trading$29.50 +0.37 (+1.27%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Keros Therapeutics NASDAQ:KROS$10.30 -0.47 (-4.36%) Closing price 04:00 PM EasternExtended Trading$10.20 -0.10 (-0.97%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Oric Pharmaceuticals NASDAQ:ORIC$7.50 -0.52 (-6.48%) Closing price 04:00 PM EasternExtended Trading$7.95 +0.45 (+6.03%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
